Neutrocheck®

Optimising triage in acute oncology

The current problem

Around 10 million people across the globe receive chemotherapy every year. Individuals undergoing chemotherapy can develop a complication called neutropenic sepsis that, if not treated urgently, rapidly becomes life-threatening. Early antibiotic treatment is critical. If the infection progresses to severe sepsis, risk of death increases by 8% for every hour that antibiotics are delayed [1].

[1] Kumar, A et al. Duration of hypotension before initiation of effective antimicrobial therapy is a critical determinant of survival in human septic shock. Crit Care Med 2006; 34(6): 1589-96.

CHEMOTHERAPY

Can temporarily suppress the immune system

NEUTROPHILS

Are the key blood cells suppressed in neutropenic sepsis

NEUTROPENIC SEPSIS

Needs to be treated urgently with broad spectrum antibiotics

There is currently no way to safely triage patients at risk of neutropenic sepsis at home.

This means that all chemotherapy patients with a fever are advised to urgently attend the Emergency Room (ER), whether they have neutropenia or not.

Here they will receive intravenous antibiotic treatment whilst awaiting lab results. This leads to many unnecessary trips to hospital and places enormous stress on emergency departments.

1 in 2 patients have normal neutrophils and may not have needed to attend the ER

1 in 2 do not receive antibiotics within the recommended one hour window, risking lives

Neutrocheck® transforms emergency care, making it safer and more effective.

What is Neutrocheck®?

A simple to use finger-prick blood test

Our proprietary device uses a simple finger-prick blood test to simultaneously assess neutrophil count and C-reactive protein (CRP) levels. Used alongside a patient-focused app, Neutrocheck® helps clinicians remotely identify patients at risk of neutropenic sepsis. It offers rapid results to support early intervention and improve patient outcomes. The solution also has the potential to significantly reduce avoidable hospital admissions.

Patient benefits

01

Earlier and remote detection

Allows measurements of neutrophil and CRP levels at home

02

Communication

Improved and personalised communication with clinicians

03

Reduced hospital visits

Helps to prevent unnecessary hospital visits

Healthcare practitioner benefits

01

Remote identification

Allows remote identification and risk stratification of patients with suspected neutropenia

02

High-risk individuals

Helps to accelerate treatment for high-risk individuals

03

Reduces antibiotics

Helps to reduce the number of patients who unnecessarily receive precautionary antibiotic treatment

Our partners

Where are we now?

Neutrocheck® is currently being tested in a clinical trial at hospital sites in the UK.

As health systems around the world seek to decentralise care and reduce emergency service burdens, Neutrocheck®’s ability to deliver actionable results in minutes represents a compelling opportunity.

If you would like to become an early adopter or find out more about Neutrocheck®, please contact us at info@52north.health